Cancer treatment reviews · 2025
The emerging role of PARP inhibitors in prostate cancer: A narrative review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lobianco Lorenzo, Calvanese Gabriele, D'Ausilio Debora, Rossetti Sabrina, Cecere Sabrina Chiara, Ventriglia Jole, Pisano Carmela, Tambaro Rosa, Napoli Marilena Di, Passarelli Anna, Roma Cristin, Luca Antonella De, Sepe Filippo, Cozzolino Silvana, Perri Erica, Lamia Maria Rosaria, Moccia Carlo, Pignata Sandro
Аннотация
Prostate cancer (PC) is the second most common cancer and the fifth leading cause of cancer mortality in men, worldwide. Genomic analysis identified alterations in DNA damage repair (DDR) pathways, in up to 30% of metastatic castration-resistant prostate cancer (mCRPC). Homologous recombination repair (HRR) mutations in BRCA1/2 emerged as a relevant biomarker in PC, linked to aggressive behavior, unfavorable outcomes and notable responses to poly-ADP ribose polymerase inhibitors (PARPi). While PARPi efficacy in BRCA-mutated mCRPC is well established, their role in earlier disease stages is currently under investigation. This non-systematic narrative review aims to summarize current evidence on PARPi in PC, outlining approved indications, ongoing clinical trials, and emerging therapeutic strategies across different disease settings.